TSX runs higher on rate cut expectations
Douglas J. Swirsky, Chief Financial Officer of Maxcyte Inc (NASDAQ:MXCT), acquired 50,000 shares of common stock on August 13, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were purchased at $1.29, for a total transaction value of $64,500. The purchase comes as the stock has declined nearly 67% over the past six months, with InvestingPro data indicating the stock is currently in oversold territory.
Following the transaction, Swirsky directly owns 161,811 shares of Maxcyte stock. The purchase was signed off by David Sandoval, Attorney-in-Fact. While the company maintains a strong liquidity position with a current ratio of 12.39 and more cash than debt on its balance sheet, InvestingPro analysis suggests the stock is trading below its Fair Value. Discover 10+ additional exclusive insights and detailed financial analysis available on InvestingPro.
In other recent news, MaxCyte Inc. reported its second-quarter 2025 earnings, revealing a revenue miss. The company posted an earnings per share of -$0.12, which was below the expected -$0.10. Revenue was $8.5 million, falling short of the $9.63 million forecast, representing an 11.73% miss. Following these results, MaxCyte reduced its 2025 revenue guidance by $5 million, anticipating a 5% year-over-year decline in its core business at the midpoint. In response to these developments, BTIG downgraded MaxCyte’s stock rating from Buy to Neutral, citing ongoing funding challenges for the company’s cell and gene therapy customers. Similarly, William Blair downgraded the stock to Market Perform, highlighting the company’s disappointing performance and reduced guidance. The revised guidance now indicates a decline in core organic revenue by 6%-16% for the year, with an anticipated 20% drop in the second half. These recent developments have raised concerns among investors and analysts about MaxCyte’s financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.